CYTEK(US:CTKB) ZACKS·2026-02-27 02:06分组1 - Cytek Biosciences reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.02, compared to earnings of $0.07 per share a year ago, resulting in an earnings surprise of -166.67% [1] - The company posted revenues of $62.14 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.23%, and showing an increase from year-ago revenues of $57.48 million [2] - Cytek Biosciences shares have declined approximately 13.5% since the beginning of the year, while the S&P 500 has gained 1.5% [3] 分组2 - The earnings outlook for Cytek Biosciences is mixed, with the current consensus EPS estimate for the coming quarter at -$0.04 on revenues of $44.44 million, and -$0.02 on revenues of $207.38 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Cytek belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]